Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells.
Immunotherapy
cancer stem cell
clinical
mechanism
target
therapeutic application
Journal
Current cancer drug targets
ISSN: 1873-5576
Titre abrégé: Curr Cancer Drug Targets
Pays: Netherlands
ID NLM: 101094211
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
01
2020
revised:
14
03
2020
accepted:
04
04
2020
pubmed:
5
5
2020
medline:
15
12
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
Tumor recurrence and drug resistance are two of the key factors affecting the prognosis of cancer patients. Cancer stem cells (CSCs) are a group of cells with infinite proliferation potential which are not sensitive to traditional therapies, including radio- and chemotherapy. These CSCs are considered to be central to tumor recurrence and the development of drug resistance. In addition, CSCs are important targets in cancer immunotherapy because of their expression of novel tumorassociated antigens, which result from mutations in cancer cells over the course of treatment. Emerging immunotherapies, including cancer vaccines, checkpoint blockade therapies, and transferred immune cell therapies, have all been shown to be more effective when they selectively target CSCs. Such therapies may also provide novel additions to the current therapeutic milieu and may offer new therapeutic combinations for treatment. This review summarizes the relationships between various immunotherapies and CSCs and provides novel insights into potential therapeutic applications for these approaches in the future.
Identifiants
pubmed: 32364076
pii: CCDT-EPUB-106333
doi: 10.2174/1568009620666200504111914
doi:
Substances chimiques
Cancer Vaccines
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-131Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.